Search for European Projects

14 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Investigating the impact of meditation training on mental health and wellbeing in the ageing population (MEDIT-AGEING)

Start date: Jan 1, 2016, End date: Dec 31, 2020,

As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimer’s disease, AD), sleep disturbances and depression, all related to psychological distress and anxiety, are significant drivers of reduced quality of life in older adults. This project builds on evidence that lifestyle factors and meditation practice have the potent ...
Read Project

 12

 FINISHED 

REgenerative Stem cell therapy for STroke in Europe (RESSTORE)

Start date: Sep 1, 2015, End date: Aug 31, 2020,

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke ...
Read Project

 29

 FINISHED 

iABC Programme (IABC PROGRAMME)

Start date: Aug 1, 2015, End date: Jul 31, 2020,

Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10,000) people in the EU. Chronic bacterial pulmonary infection leading to an irreversible decline in lung structure and function is the main cause of mortality and morbidity in patients with CF, with more than 95% of deaths due to respiratory failure. Pseudomon ...
Read Project

 21

 FINISHED 

Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial (WAKE-UP)

Start date: Dec 1, 2011, End date: Nov 30, 2017,

WAKE-UP is an investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial designed to test efficacy and safety of MRI-based intravenous thrombolysis in patients with wake-up stroke. Every year 1.5 million patients suffer a stroke in the EU. Up to 20% of stroke patients wake up with stroke symptoms. Currently these patients are excluded from thrombolysis which is the onl ...
Read Project

 13

 FINISHED 

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified (CFMATTERS)

Start date: Oct 1, 2013, End date: Jun 30, 2017,

Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caus ...
Read Project

 15

 FINISHED 

Clinical European study on the outcome of surgical and hormonal therapy and psychological intervention in disorders of sex development (DSD) (DSD-LIFE)

Start date: Oct 1, 2012, End date: Mar 31, 2017,

Disorders of sex development (DSD) are a conglomerate of rare diseases with an estimated incidence of 1: 4500. The causes of DSD are mainly disorders with gonadal dysgenesis, decreased androgen synthesis or function in XY males or disorders with elevated androgen production in XX females. Decision on sex of rearing is difficult in some cases as the prenatal androgen imbalances result in ambiguous ...
Read Project

 17

 FINISHED 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Start date: Jan 1, 2010, End date: Nov 30, 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Read Project

 34

 FINISHED 

Biopharmaceutical therapy for treatment of Primary Hyperoxaluria (ELIMOX)

Start date: Oct 1, 2013, End date: Sep 30, 2016,

"Interest in the use of naturally occurring human gut bacteria as pharmaceutical drugs has increased as knowledge about the human microbiota and its role in health and disease has advanced.The ELIMOX project proposes to develop a new drug from Oxalobacter formigenes, an anaerobic bacterium whose only carbon source is oxalate, for the treatment of primary hyperoxaluria (PH). PH is a rare and life-t ...
Read Project

 12

 FINISHED 

Clinical development of Enzyme Replacement Therapy in alpha-Mannosidosis patients using recombinant human enzyme (ALPHA-MAN)

Start date: Oct 1, 2010, End date: Mar 31, 2014,

Alpha-Mannosidosis is a rare Lysosomal Storage Disorder with a worldwide incidence of about 1:500 000. This orphan and devastating disease is caused by the deficiency of the lysosomal alpha-mannosidase (LAMAN) which is responsible for the intralysosomal degradation of mannosyl linked oligosaccharides. To date no causative treatment for alpha-Mannosidosis is available and since most of the children ...
Read Project

 12

 FINISHED 

EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances (EURIPIDES)

Start date: Feb 1, 2008, End date: Jul 31, 2012,

"We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeutic interventions. Multidrug transporters actively transport substrates (including multiple CNS drugs) against concentration gradients across the blood-brain barrier (BBB). ...
Read Project

 14

 FINISHED 

Development of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children (LOULLA&PHILLA)

Start date: Nov 1, 2008, End date: Apr 30, 2012,

"Only for Children Pharmaceuticals, a French based Small and Medium-sized Enterprise (SME) developing drug for children, is the Coordinator of a multinational, multidisciplinary and complementary Consortium. This Consortium is composed of highly qualified organizations and notorious clinicians in pediatric hemato-oncology. The Consortium is an integrated team of competencies (clinicians, pædiatric ...
Read Project

 12

 FINISHED 

Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics (Mitotarget)

Start date: Feb 1, 2009, End date: Mar 31, 2012,

Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question re ...
Read Project

 19

 FINISHED 

Investigation of the molecular pathogenesis and pathophysiology of Disorders of Sex Development (DSD) (EuroDSD)

Start date: May 1, 2008, End date: Oct 31, 2011,

Disorders of Sex Development (DSD) constitute a group of rare to very rare mostly heritable disorders affecting the genito-urinary tract and in most instances also the endocrine-reproductive system. We hypothesize that stringent and stepwise analysis of cases with DSD will result in a systematic and reliable discovery of DSD-relevant biochemical, genetic and functional profiles, allowing for the d ...
Read Project

 14

 FINISHED 

"European Networks of Centres of Expertise for CF (Cystic Fibrosis), LAM (Lymphangioleiomyomatosis), and LTX (Lung Transplantation)" (ENCE-CF-LAM-LTX)

Start date: Apr 1, 2009, End date: Mar 31, 2011,

"European Centres of Expertise Networks for rare diseases have been identified by the European Commission as one important area of future activity in the attempt of achieving one of the main objectives across the EC endeavour of “Optimising the delivery of health care to European Citizens”. It is obvious that especially in rare diseases the joined forces of the experts networking throughout Europe ...
Read Project

 8